Needham analyst Serge downgraded Adamas Pharmaceuticals to Hold after the management pulled its forecast for 2% Rx market share for the company’s Gocovri given its reported weakness in Q4 and expectations for Q1. The analyst states that the seasonal factors related to early-year insurance plan resets and pharma industry changes, along with the timing of Osmolex launch, have further disrupted Gocovri performance. Belanger notes that the lack of visibility on the product takes his rating to neutral until he sees some signs that the Gocovri launch ramp can re-accelerate.
https://thefly.com/landingPageNews.php?id=2874309
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.